linjc16/ctgov huggingface dataset:
Use of Ultrasound Guidance to Facilitate Obtaining Peripheral Intravenous Access

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if the use of ultrasound guidance to insert peripheral intravenous catheters will decrease the number of punctures required to successful insertion. The hypothesis is that fewer attempts will be required with the use of ultrasound potentially leading to preservation of vessels, decreased patient pain scores and increased patient/parent satisfaction.

Detailed Description
-----------------
Patients with known or current difficult venous access will be referred to the Vascular Access Team for peripheral intravenous catheter insertion. The Vascular Access Team will randomize patients to ultrasound guidance or non-ultrasound guidance for placement of the peripheral intravenous catheter.

Official Title
-----------------
Use of Ultrasound Guidance to Facilitate Insertion of Peripheral Intravenous Catheter in Pediatric Patients

Conditions
-----------------
Catheterization, Peripheral

Intervention / Treatment
-----------------
* Device: Ultrasound guidance
* Procedure: Non-ultrasound guidance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients 0-17 years of age requiring peripheral intravenous access have not had PIV attempt in preceding 24 hours Exclusion Criteria: patients who are medically unstable patients who require emergent intravenous access

Ages Eligible for Study
-----------------
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ultrasound guidance<br>Ultrasound guidance used to facilitate insertion of PIV catheter. | Device: Ultrasound guidance<br>* Ultrasound guidance used to facilitate insertion of PIV catheter<br>|
| Active Comparator: Non-ultrasound guidance<br>Ultrasound guidance will not be used for insertion of PIV catheter. | Procedure: Non-ultrasound guidance<br>* Ultrasound guidance will not be used for insertion of PIV catheter<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of attempts to successful peripheral intravenous access cannulation. |  | 1 time - baseline visit | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient pain score rating for PIV access attempt. |  | 1 time - baseline visit |
Study to Evaluate Satisfaction After Treatment With Restylane

Study Overview
=================
Brief Summary
-----------------
Open-label, phase IV, post-marketing study to evaluate aesthetic improvement and satisfaction after treatment with Restylane

Official Title
-----------------
A Study Comparing Hyaluronic Acid Effectiveness & Evaluating Cheek Results With Restylane

Conditions
-----------------
Cheek Augmentation

Intervention / Treatment
-----------------
* Device: Restylane Volyme
* Device: Restylane Lyft Lidocaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed and dated informed consent to participate in the study Adult women who intend to undergo cheek augmentation Exclusion Criteria: Subjects presenting with known allergy to HA (hyaluronic acid) filler or amide local anesthetics Subjects with a previous implant other than HA in or near the intended treatment site Participation in any other clinical study within three (3) months before treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Restylane Volyme<br>Hyaluronic Acid | Device: Restylane Volyme<br>* Hyaluronic Acid: Injectable gel for contouring effect (of cheek volumization).<br>|
| Experimental: Restylane Lyft Lidocaine<br>Hyaluronic Acid | Device: Restylane Lyft Lidocaine<br>* Hyaluronic Acid: Injectable gel for projection effect (of cheek augmentation).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess Treatment With Restylane Volyme and Restylane Lyft Lidocaine Using GAIS | The 7-grade Global Aesthetic Improvement Scale (GAIS) assess the appearance of the treatment area (cheeks) compared to pre-treatment. The rating is very much improved, much improved, improved, no change, worse, much worse, or very much worse. | 4 weeks after last treatment |
Visual Field Restoration in Patients With Post-stroke Homonymous Hemianopsia

Study Overview
=================
Brief Summary
-----------------
This study will assess the effectiveness of a stimulus, in the blind field of hemianopsic patients, to restore the vision of patients with homonymous hemianopsia consecutive to stroke (unilateral occipital lesion). Hemianopsia occurs in 30% of strokes regardless of the cerebral localization and in 60% of stroke interesting the territory of the posterior cerebral artery.

Official Title
-----------------
Visual Field Restoration in Patients With Post-stroke Homonymous Hemianopsia

Conditions
-----------------
Hemianopsia

Intervention / Treatment
-----------------
* Other: stimulation of the blind visual field


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presence of an homonymous visual field amputation after vascular retrochiasmatic lesion of the occipital region (visual cortex alone or with optical radiations or with other associated occipital areas) inclusion 3 months to 36 months after stroke Patients aged 18 years and older Exclusion criteria: Brain injury history Severe neuropsychological, psychiatric or behavioral disorder Severe eye disorder or visual impairment (visual acuity less than 3/10) Progressive eye disorder (cataracts or glaucoma) insufficient French language proficiency to understand the questionnaires and rehabilitation tasks patient under legal protection patient's opposition to participate in the study no medical insurance coverage pregnant pr breastfeeding patient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: immediate rehabilitation<br> | Other: stimulation of the blind visual field<br> <br> |
| Other: delayed rehabilitation<br> | Other: stimulation of the blind visual field<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in the sensitivity of detection of a visual stimulus after rehabilitation | change in the mean number of points where the sensitivity is lower than 15db in each contralesional hemifield, before and after rehabilitation | change from baseline sensitivity at week 22 |
Effects of Labetalol on Human Cocaine Use - 8

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effect of labetalol treatment on the subjective and physiological effects of cocaine.

Detailed Description
-----------------
The goal of this study was to investigate the safety and utility of labetalol an alpha and beta adrenergic block, for cocaine dependence in humans. A total of 12 subjects were enrolled in this double blind, placebo controlled outpatient study. After baseline measures are obtained, three experimental sessions were held at least 2 days apart. Subjects were administered a single low (100 mg) or high dose of labetalol (200mg) or placebo on each of 3 experimental sessions. The labetalol doses were given in ascending order and the placebo treatment were randomly inserted into the sequence. A single dose of smoked cocaine (0.4 mg/kg) was administered 2 hrs after labetalol or placebo treatment. During the sessions, several subjective, behavioral and physiological measures were obtained.

Official Title
-----------------
Effects of Labetalol on Human Cocaine Use

Conditions
-----------------
Cocaine-Related Disorders

Intervention / Treatment
-----------------
* Drug: Labetalol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male/Female ages 20-55. History of smoked or intravenous cocaine use on the average of at least once a week over a six month period. Current history of good health and normal EKG. Not pregnant as determined by pregnancy screening nor breat feeding and using acceptable birth control methods (e.g. birth control pills diaphragm, condoms, plus foam) during the study. Exclusion Criteria: Current problems with major psychiatric illnesses including bipolar disorder, schizophrenia, or anxiety disorders. Current dependence on alcohol or on durgs other than cocaine. History of major medical illnesses including asthma and chronic obstructive pulmonary disease. Currently on a drug related parole or probation. Treated for chemical dependency within the past 6 months.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Labetalol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective |  |  | 
| Physiological measures |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cocaine dependence
Relative Risk of Hypertension Among Obese

Study Overview
=================
Brief Summary
-----------------
Observational study was conducted to determine the relative risk of hypertension among young adult obese population of Pakistan with age between 25-40 years

Official Title
-----------------
Relative Risk of Hypertension Among Young Adult Obese Population

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Other: Observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult population with age between 25- 40 years having normal weight or Obesity of grade I and II, with or without hypertension. Exclusion Criteria: Patients with co-morbid like Diabetes mellitus, dyslipidemia, and cardiovascular disorder were excluded from the study

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Obese young adult<br> | Other: Observation<br>* observational study<br>|
| Non Obese young adult<br> | Other: Observation<br>* observational study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hypertension | International Society of Hypertension Global Hypertension Practice Guidelines 2020 | day 1 |
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

Study Overview
=================
Brief Summary
-----------------
The objective of this non-interventional study is to examine whether use of Phosphodiesterase Inhibitors (PDE5s), including use of sildenafil, vardenafil, or tadalafil, triggers the onset of acute NAION.

Detailed Description
-----------------
Sites will identify patients who meet the entry criteria during the conduct of their normal practice. Patients meeting these criteria will be offered participation in the study after reading and completing an informed consent document.

Official Title
-----------------
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential Trigger Factor for Acute NAION

Conditions
-----------------
Optic Neuropathy, Ischemic

Intervention / Treatment
-----------------
* Drug: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male aged ≥45 years; Experienced abrupt visual change in only 1 eye Exclusion Criteria: Pain determined by an ophthalmologist to be consistent with an inflammatory/arteritic process or optic neuritis; History of NAION or optic neuritis. Participation in other studies within 60 days prior to entry in the study.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Case Group<br> | Drug: No intervention<br>* No intervention occurs in this observational study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Days Exposed to PDE5i During 1-Day Case Window and 29 1-Day Control Windows Among Participants Adjudicated as Definite NAION Cases | Adjudication committee classified participants as Definite, Possible, or Non-NAION cases, or insufficient information available or unable to adjudicate. Case window: 1 day preceding symptom onset day; 29 control windows: 29 days preceding case window. A case or control window was considered exposed if: sildenafil/vardenafil was used on that day and/or previous day; tadalafil was used on that day and/or any of previous 4 days. In this analysis, each participant contributed exposure information for 1 case window and 29 control windows. | 30-day period prior to onset of NAION symptoms | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Optic Neuropathy Acute NAION PDE5 Inhibitor
Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

Study Overview
=================
Brief Summary
-----------------
Assured treatment with Risperal CONSTA will provide first-episode patients, who have a greater potential for therapeutic response, with their best opportunity for continued improvement in cognitive function beyond three months of treatment.

Detailed Description
-----------------
First episode patients have a greater potential for therapeutic response than multi-episode patients, and many of them also havea great desire to rejoin the workforce. Unfortunately, first episode patients become non-compliant or intermittently compliant with prescribed antipsychotic treatment at least as frequently as multi-episode patients. We believe that assured treatment with Risperal CONTSTA will provide first episode patients wiwth their best opporutnity for continued improvement in cognitive function beyond 3 months of treatment and that improvements in cognitive function will be associated with a greater likelihood of employment, real-world outcomes, such as independent living, as well as measures of brain function.

Official Title
-----------------
Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: Antipsychotic/Risperidone Consta


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male or female between 18-40 years of age meet DSM-IV criteria for first-episode schizophreniform, schizophrenia or schizoaffective disorder Exclusion Criteria: pregnant & breast-feeding women patients with known sensitivity to oral Risperdal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Antipsychotic/Risperidone Consta|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Schizophreniform; Schizophrenia; Schizoaffective Disorders
The Influence of Vision on Balance, Gait and Falls

Study Overview
=================
Brief Summary
-----------------
Falls are the most serious and frequent home accident amongst elderly. Most falls occur during walking. Vision is reduced with ageing and visual impairments affect balance. Uncorrected visual deficits and balance problems are reported to be risk factors for falls and fall related fractures. The present project uses a longitudinal design and aims at assessing the impact of cataract surgery on balance and gait as risk factors for falls.

Detailed Description
-----------------
A longitudinal design is used, where subjects referred to the Cataract Unit are tested 1-3 weeks in advance of the surgery, and 4-6 weeks and 12 months after the surgery. Outcome measures are visual function, falls, balance and gait. Secondary outcome is quality of life, fear of falling and daily life functioning

Official Title
-----------------
The Effect of Cataract Surgery on Gait, Balance and Falls in Older Persons

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Procedure: Cataract surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >70 years of age referred to cataract surgery on one or both eyes able to walk unassisted at least 10 m Exclusion Criteria: terminal illness have undergone orthopedic surgery in the lower limbs the last 12 months Have had a stroke last 12 months dementia (measured by MMSE <20

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| post cataract surgery<br> | Procedure: Cataract surgery<br>* surgery one one or two eyes by use of two different types of lenses and correcting for refraction<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Falls |  | over one year | 
| Visual function |  | pre surgery, 6-9 weeks and 1 year post surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health related Quality of Life |  | pre surgery, 6-9 weeks and one year after surgery | 
| Gait |  | pre surgery, 6-9 weeks and one year after surgery | 
| Fear of falling |  | pre surgery, 6-9 weeks and one year after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Effect, Balance, Gait, Falls
Retarded Phosphatidylcholine in Steroid-Dependent Chronic Active Ulcerative Colitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate if retarded release phosphatidylcholine is an effective alternative to steroid dependent or -refractory course in chronic active ulcerative colitis. The hypothesis is, that ulcerative colitis is caused by a barrier defect of the colonic mucus layer. The background of the study is the finding, that the phosophatidylcholine content of the colonic mucus is strongly reduced in ulcerative colitis (UC) compared to healthy controls and patients with Crohn´s disease. The content was measured in non-inflamed areas of the colon in UC. Thus, we evaluate whether a substitution of colonic PC is an effective method for steroid dependent UC. See: Gut. 2005 Jul;54(7):966-71. Stremmel et al.

Detailed Description
-----------------
Design: Prospective, randomized, placebo-controlled, double-blinded study. Population: 60 patients with chronic active ulcerative colitis and steroid dependency Inclusion: Chronic active ulcerative colitis, clinical index 5 or more, endoscopic Index 5 or more, steroid dependent course since at least 4 months. Main criteria: complete steroid reduction

Official Title
-----------------
Prospektive, Randomisierte Doppelblinde Studie Zur Wirksamkeit Von Intestinal Retardiert Freigesetztem Phosphatidylcholine Bei therapierefraktärer Colitis Ulcerosa Mit Chronisch Aktivem Verlauf Unter Corticosteroiden

Conditions
-----------------
Ulcerative Colitis, Phosphatidylcholine

Intervention / Treatment
-----------------
* Drug: Retarded Release Phosphatidylcholine (rPC)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed Letter of Content diagnosis of ulcerative colitis (clinical, endoscopic and histologic evidence) chronic active and steroid dependent course over at least 4 months (CAI > 4, EAI > 4) Exclusion Criteria: infectious colitis toxic megacolon ulcerative proctitis or less than 20cm inflamed

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Retarded Release Phosphatidylcholine (rPC)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complete steroid reduction |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| remission, life quality, clinical indices, endoscopic indices, histological score, subgroup analysis |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
steroid, retarded phosphatidylcholine, chronic active